• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

FDA Approves TENEO Excimer Laser Platform from Bausch + Lomb

News
Article

The device is intended for use for LASIK vision correction surgery for myopia and myopic astigmatism.

(Image Credit: AdobeStock/wladimir1804)

(Image Credit: AdobeStock/wladimir1804)

Bausch + Lomb Corporation announced the FDA has approved the TENEO Excimer Laser Platform for LASIK vision correction surgery for myopia and myopic astigmatism.

Luc Bonnefoy, president, Global Surgical, Bausch + Lomb discussed the impact of the decision in a press release from B+L.

“TENEO has been well received and is widely adopted in more than 50 countries around the world, and now U.S. ophthalmologists will benefit from this versatile laser," said Bonnefoy. “The precise engineering of this platform delivers a fast, small, technologically advanced machine that provides an exceptional experience for both surgeons and patients.”1

According to B+L, the TENEO device offers several unique features not offered by previous excimer laser platforms, including improvements on accuracy, efficiency, and usability.

The TENEO device operates at 1,740Hz, which is more than “three times the speed of the laser’s repetition” which helps to “ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.” Furthermore, the platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter, states the company.1-2

In addition to the laser speed, the TENEO sports a “compact design” making it the smallest excimer laser unit available in the United States.1-2

George Waring IV, MD, ophthalmologist and founder and medical director, Waring Vision Institute, Mt Pleasant, SC, commented on the approval.

“FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said Waring IV. “In addition to the technological advantages TENEO offers, the open air feeling around the laser and quiet performance contribute to a comfortable experience for the patient.”1

Those interested can submit information online to be among the first to adopt TENEO.

References:
  1. Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery. Press release; January 8, 2024. Accessed January 8, 2024.
    https://www.businesswire.com/news/home/20240108249683/en/Bausch-Lomb-Receives-FDA-Approval-for-TENEO%E2%84%A2-Excimer-Laser-Platform-for-Myopia-and-Myopic-Astigmatism-LASIK-Vision-Correction-Surgery
  2. TENEO an extension of brilliance. Accessed January 8, 2024. https://www.bauschsurgical.com/refractive/teneo/

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
New optics textbook aims to be a compendium resource for the topic
© 2024 MJH Life Sciences

All rights reserved.